MX2020001305A - Metodos para tratar la esofagitis eosinofilica activa. - Google Patents

Metodos para tratar la esofagitis eosinofilica activa.

Info

Publication number
MX2020001305A
MX2020001305A MX2020001305A MX2020001305A MX2020001305A MX 2020001305 A MX2020001305 A MX 2020001305A MX 2020001305 A MX2020001305 A MX 2020001305A MX 2020001305 A MX2020001305 A MX 2020001305A MX 2020001305 A MX2020001305 A MX 2020001305A
Authority
MX
Mexico
Prior art keywords
methods
eosinophilic esophagitis
present
treating active
active eosinophilic
Prior art date
Application number
MX2020001305A
Other languages
English (en)
Spanish (es)
Inventor
Radin Allen
Mannent Leda
D Hamilton Jennifer
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2018/045195 external-priority patent/WO2019028367A1/en
Publication of MX2020001305A publication Critical patent/MX2020001305A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2020001305A 2017-08-04 2018-08-03 Metodos para tratar la esofagitis eosinofilica activa. MX2020001305A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762541242P 2017-08-04 2017-08-04
US201762561593P 2017-09-21 2017-09-21
EP18305252 2018-03-08
PCT/US2018/045195 WO2019028367A1 (en) 2017-08-04 2018-08-03 METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES

Publications (1)

Publication Number Publication Date
MX2020001305A true MX2020001305A (es) 2020-03-09

Family

ID=63113646

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020001305A MX2020001305A (es) 2017-08-04 2018-08-03 Metodos para tratar la esofagitis eosinofilica activa.
MX2024012777A MX2024012777A (es) 2017-08-04 2020-01-31 Uso de un inhibidor de la via de interleucina-4/interleucina-13 (il-4/il-13) para tratar la esofagitis eosinofilica activa

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024012777A MX2024012777A (es) 2017-08-04 2020-01-31 Uso de un inhibidor de la via de interleucina-4/interleucina-13 (il-4/il-13) para tratar la esofagitis eosinofilica activa

Country Status (9)

Country Link
EP (1) EP3661551A1 (enExample)
JP (2) JP7417515B2 (enExample)
KR (2) KR102719720B1 (enExample)
CN (1) CN111032084A (enExample)
AU (2) AU2018311981B2 (enExample)
CA (1) CA3071528A1 (enExample)
IL (2) IL315556A (enExample)
MA (1) MA49744A (enExample)
MX (2) MX2020001305A (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7862322B2 (ja) * 2020-05-22 2026-05-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法
GB202102277D0 (en) * 2021-02-18 2021-04-07 Nordic Bioscience As Immunoassay for detecting Eosinophilic Esophagitis
EP4091615A1 (en) * 2021-05-20 2022-11-23 Dr. Falk Pharma Gmbh Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitis
CN117085122A (zh) * 2022-04-29 2023-11-21 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
JP6715767B2 (ja) * 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
CN107428828A (zh) * 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白

Also Published As

Publication number Publication date
RU2020109331A (ru) 2021-09-06
IL315556A (en) 2024-11-01
JP2024016237A (ja) 2024-02-06
AU2025200955A1 (en) 2025-03-06
EP3661551A1 (en) 2020-06-10
IL272245A (en) 2020-03-31
AU2018311981B2 (en) 2024-11-14
AU2018311981A1 (en) 2020-02-20
MX2024012777A (es) 2024-11-08
KR102719720B1 (ko) 2024-10-22
CA3071528A1 (en) 2019-02-07
JP7417515B2 (ja) 2024-01-18
JP2020529434A (ja) 2020-10-08
IL272245B2 (en) 2025-02-01
IL272245B1 (en) 2024-10-01
KR20240152980A (ko) 2024-10-22
KR20200035442A (ko) 2020-04-03
JP7811933B2 (ja) 2026-02-06
CN111032084A (zh) 2020-04-17
MA49744A (fr) 2020-06-10
RU2020109331A3 (enExample) 2021-12-28

Similar Documents

Publication Publication Date Title
CY1122909T1 (el) Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r
ZA202208792B (en) Methods of treating and preventing graft versus host disease
PH12022550098A1 (en) Parp1 inhibitors
MX393693B (es) Anticuerpo anti-il-13 para usarse en el tratamiento de esofagitis eosinofílica
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EP4324845A3 (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
MY167390A (en) Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
EP4434344A3 (en) Compositions comprising recombinant bacillus cells and an insecticide
MY195443A (en) Tissue Factor Pathway Inhibitor Antibodies and uses Thereof
MX2024012777A (es) Uso de un inhibidor de la via de interleucina-4/interleucina-13 (il-4/il-13) para tratar la esofagitis eosinofilica activa
MX2016011537A (es) Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras.
CY1126231T1 (el) Παραλλαγες ανθρωπινης αλφα-γαλακτοσιδασης
EA201890728A3 (ru) Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами
ZA201904522B (en) Heterocyclic inhibitors of mct4
MX2022004373A (es) Celulas madre modificadas y metodos de uso de las mismas.
UA122488C2 (uk) Композиція для підвищення ефективності приживання гемопоетичних стовбурових клітин після трансплантації
MX2021015210A (es) Inhibidores de la via de respuesta al estres integrada.
MX2020013269A (es) Inhibidores de la vía de respuesta al estrés integrada.
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
TN2014000086A1 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
WO2020021480A3 (en) Compositions and methods for treating the eye
MX2024014054A (es) Inhibidores de sintasa de oxido neuronal para inmunoterapia
WO2017021855A3 (en) Motile sperm domain containing protein 2 and inflammation